Ribociclib

Overview

Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.[1][2] WP

The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash.[3] WP

Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.[3–8] WP

Drug class

Antineoplastic, CDK inhibitor WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

In the United States, it is indicated for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.[1][4] WP

In the European Union, it is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.[3] WP

In September 2024, the US Food and Drug Administration (FDA) expanded the indication for ribociclib, in combination with an aromatase inhibitor, for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA approved the ribociclib and letrozole co-pack for the same indication.[9] WP

In November 2024, the European Commission expanded the indication of ribociclib, in combination with an aromatase inhibitor, for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.[3][10][11] WP

Risks and side effects

Side effects

The most common side effects in studies were decreased blood cell counts, mainly neutropenia (in 75% of patients, as compared to 5% under placebo), but also anemia (18% vs. 5%). Gastrointestinal disorders were also common, for example nausea (52% vs. 29%) and diarrhea (35% vs. 22%), as was alopecia (33% vs. 16%). The drug also increases the QT interval and liver enzymes (alanine transaminase, aspartate transaminase).[1][6] WP

The most common side effects include infections, low levels of white blood cells, headache, cough, nausea, vomiting, diarrhoea, constipation, tiredness, hair loss and rash. The most common severe side effects include infections, low levels of red and white blood cells, vomiting, abnormal blood tests for liver function and low levels of phosphate in the blood (hypophosphataemia).[3] WP

Interactions

Interactions

As ribociclib is mainly metabolized by the liver enzyme CYP3A4, inhibitors of this enzyme increase its concentrations in the body and could potentiate side effects and toxicity. Examples of such inhibitors include ketoconazole and similar antifungal drugs, ritonavir, clarithromycin, as well as grapefruit. Conversely, drugs that induce CYP3A4, such as rifampicin and St John's Wort, can decrease ribociclib concentrations.[1][6] WP

Ribociclib itself is a moderate to strong CYP3A4 inhibitor and can increase concentrations of other drugs that share this metabolism, as has been shown with midazolam. It also inhibits a number of transporter proteins and could thus theoretically interfere with the transport of other drugs in the body. It could also amplify QT prolongation of other drugs such as antiarrhythmics, clarithromycin, and haloperidol.[1][6] WP

Pharmacology

Pharmacodynamics

Cyclin-dependent kinases (CDKs) 4 and 6 are enzymes that have been shown to promote cell division and multiplication in both normal and cancer cells. Many cancer cells have shown abnormalities that increase the activity of CDK, leading to the inactivation of certain tumor suppressor genes.[12][13] WP

When used in combination with other drugs such as an ALK inhibitor or an MEK inhibitor, ribociclib has been shown to have a synergistic effect, resulting in improved responses. Again, this is likely a result of "crosstalk" between signaling pathways. Simply blocking one pathway in cancer tumorigenesis can sometimes result in "tumor compensation", where the tumor compensates for the blocked signaling pathway by utilizing other pathways to survive. By blocking several pathways at once, it is thought that the tumor is less able to compensate, and a greater anti-tumor response is often observed. Utilizing ribociclib in combination with other agents has been shown to reduce the development of resistance to these agents.[12][14][15] WP

Pharmacokinetics

The percentage of ribociclib absorbed in the gut has not been determined. Highest blood plasma levels are reached after one to four hours; and after repeated dosage, steady state concentrations are reached after about eight days. Food intake has no effect on absorption rates. When in the bloodstream, about 70% of ribociclib is bound to plasma proteins.[1][6] WP

The substance is mainly metabolized by CYP3A4 and subsequently by various phase II enzymes, resulting in a large number of metabolites. Those with highest blood plasma concentrations in humans are called CCI284 (an unspecified N-hydroxylation product), LEQ803 (the N-demethylation product) and M1 (a glucuronide). All metabolites have negligible clinical activity.[1][6] WP

Ribociclib has a slight tendency to accumulate in the body. It is eliminated with an average biological half-life of 32 hours, mostly (69%) via the feces, but also (23%) via the urine. The unchanged drug accounts for 17% of the substance in the feces and 12% of the substance in the urine, the rest being metabolites.[1][6] WP

History

History

Ribociclib demonstrated a clinical benefit on overall survival across all three phase III trials of the MONALEESA clinical program with different endocrine therapy partners, regardless of menopausal status or line of therapy. The European Society of Medical Oncology (ESMO) assigned the highest score on the 'Magnitude of Clinical Benefit Scale' for ribociclib.[16][17] WP

In the clinical trial relevant for the drug's approval, ribociclib significantly improved progression-free survival, that is, the time span the cancer did not get worse. For participants receiving placebo plus letrozole, progression-free survival was 16 months on average, while under ribociclib plus letrozole, progression-free survival was 25 months as of the January 2017 analysis.[6] WP

In October 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended a change to the terms of the marketing authorization for ribociclib to add the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, at high risk of disease recurrence. The marketing authorization holder is Novartis Europharm Limited. In November 2024, the European Commission expanded the marketing authorization to include the use of ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor -positive, human epidermal growth factor receptor 2 -negative early breast cancer at high risk of recurrence.[10][18] WP

Chemistry

Formula

C23H30N8O PC

CAS number

1211441-98-3 PC

Molar mass (g/mol)

434.5 PC

IUPAC name (computed by PubChem)

7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide PC

SMILES

CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 PC

InChIKey

RHXHGRAEPCAFML-UHFFFAOYSA-N PC

PubChem CID

44631912

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Kisqali- ribociclib tablet, film coated. 4 May 2023
2. Other Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer. 1 November 2016
3. Journal / agency Kisqali EPAR. 31 March 2023
4. Journal / agency Kisqali (ribociclib) Tablets. 28 March 2017
5. Other FDA Clears Novartis Kisqali for Combination Breast Cancer Therapy. 14 March 2017
6. Journal / agency Kisqali: EPAR – Product Information. 31 August 2017
7. Other Thousands of breast cancer patients to have routine access to NICE-approved drug combination
8. Other Life-extending drug for incurable breast cancer approved for NHS use. 26 February 2021
9. Journal / agency FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer. 17 September 2024
10. Journal / agency Kisqali - opinion on variation to marketing authorisation. 17 October 2024
11. Other Novartis Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
12. Journal / agency Samson K. LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers. Oncology Times. 2014. doi:10.1097/01.COT.0000444043.33304.c1
13. Journal / agency Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, Parasuraman S, Howard S, Keen N, Sellers W, Brain C. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer. Molecular Cancer Therapeutics. 2014. doi:10.1158/1535-7163.TARG-13-PR02
14. Journal / agency Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, Matano A, Bhansali S, Parasuraman S, Kim K. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity. Journal of Clinical Oncology. 2014. doi:10.1200/jco.2014.32.15_suppl.9009
15. Journal / agency Wood AC, Krytska K, Ryles H, Sano R, Li N, King F, Smith T, Tuntland T, Kim S, Caponigro G, He YQ. Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma. Cancer Research. 2014. doi:10.1158/1538-7445.AM2014-1000
16. Journal / agency Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, Loi S, Visco F, Bee-Munteanu V, Afenjar K, Fresco R, Taran T, Chakravartty A, Zarate JP, Lteif A, Hortobagyi GN. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic Advances in Medical Oncology. May 2023. doi:10.1177/17588359231178125 · PMID 37275963 · PMC10233570
17. Other ESMO-Magnitude of Clinical Benefit Scale
18. Other Novartis Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence. 27 November 2024

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.